<DOC>
	<DOCNO>NCT00185445</DOCNO>
	<brief_summary>The purpose study demonstrate oral fludarabine phosphate comparable i.v . formulation use combination mitoxantrone term efficacy , safety risk/benefit profile</brief_summary>
	<brief_title>Efficacy Safety Study Oral Fludarabine Phosphate Combination With Mitoxantrone First Line Treatment Follicular NHL</brief_title>
	<detailed_description>As 29 May 2009 , clinical trial sponsor Genzyme Corporation . NOTE : This study originally post sponsor Schering AG , Germany , subsequently rename Bayer Schering Pharma AG , Germany .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Indolent Bcell follicular nonHodgkin 's lymphoma ( grade III accord REAL classification ) Stage II IV accord Ann Arbor stag system WHO performance status grade 0 , 1 2 life expectancy great 6 month Patients receive previous treatment follicular NHL Patients severe lifethreatening cardiac , pulmonary , neurological , psychiatric metabolic disease Pregnant lactate woman Women childbearing potential , men , agree take adequate contraceptive precaution least 6 month cessation therapy Laboratory screen positive Hepatitis B , C HIV infection Patients autoimmune thrombocytopenia hemolytic anemia clinical evidence . NB . A positive Coombs test alone ( clinical evidence hemolysis ) would preclude entry study . Histological transformation aggressive Bcell lymphoma Patients prior malignancy except non melanoma skin tumor stage 0 ( situ ) cervical carcinoma Impairment hepatic function unless disease relate indicated bilirubin , ASAT , ALAT gammaGT raise 2 time upper limit local laboratory range Impairment renal function indicate serum creatinine &lt; 30 ml/min Patients require systemic longterm therapy glucocorticoid Participation time another study investigational drug use Patients unable regularly attend outpatient clinic treatment assessment Any coexist medical psychological condition would preclude participation study compromise ability give inform consent Patients active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Non Hodgkin Lymphoma</keyword>
</DOC>